{"id":58801,"date":"2025-12-15T20:26:27","date_gmt":"2025-12-15T18:26:27","guid":{"rendered":"https:\/\/www.fyb.de\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/"},"modified":"2025-12-15T20:26:54","modified_gmt":"2025-12-15T18:26:54","slug":"ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/","title":{"rendered":"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals"},"content":{"rendered":"<p>Berlin\/ Zurich \u2014 The Belgian invest\u00adment and holding company Acker\u00admans &amp; van Haaren NV has inves\u00adted EUR 36 million in the biotech company DISCO Phar\u00admaceu\u00adti\u00adcals GmbH as co-lead inves\u00adtor in a seed finan\u00adcing round. Gleiss Lutz advi\u00adsed Acker\u00admans &amp; van Haaren NV compre\u00adhen\u00adsi\u00advely on this transaction.&nbsp;<\/p>\n<p>Through its subsi\u00addiary AvH Growth Capi\u00adtal, Acker\u00admans &amp; van Haaren will, subject to certain condi\u00adti\u00adons, invest up to EUR 9 million in seve\u00adral tran\u00adches and initi\u00adally hold a 12.4 percent stake.<\/p>\n<p>DISCO Phar\u00admaceu\u00adti\u00adcals was foun\u00added in May 2022 as a spin-off from ETH Zurich. With sites in Colo\u00adgne (Germany) and Schlie\u00adren (Switz\u00ader\u00adland), DISCO Phar\u00admaceu\u00adti\u00adcals uses ground\u00adbrea\u00adking<g id=\"gid_0\"> proteo\u00admics tech\u00adno\u00adlogy<\/g> to map cancer cell surface\u00ado\u00admes. The new funds will enable the further deve\u00adlo\u00adp\u00adment of seve\u00adral ADC drug candi\u00adda\u00adtes for small cell lung cancer and colo\u00adrec\u00adtal cancer through to IND-enab\u00adling studies.&nbsp;<\/p>\n<p><strong>About Acker\u00admans &amp; van Haaren<\/strong><\/p>\n<p>Acker\u00admans &amp; van Haaren is a diver\u00adsi\u00adfied group of compa\u00adnies that, among other things, provi\u00addes growth finan\u00adcing for sustainable compa\u00adnies in various sectors. It is listed on Euron\u00adext Brussels and the BEL20 index. In 2024, the group gene\u00adra\u00adted a net profit of EUR 460 million with a turno\u00adver of EUR 7.6 billion and employed a total of over 24,000 people. \u2014 https:\/\/www.avh.be\/en   <\/p>\n<p><strong>Advi\u00adsor to Acker\u00admans &amp; van Haaren: Gleiss Lutz<\/strong><\/p>\n<p>Led by <strong>Dr. Martin Viciano Gofferje, <\/strong>part\u00adner (photo: Gleiss Lutz) and Dr. Chris\u00adtoph Prawit Meiss\u00adner (both M&amp;A, both Berlin).<\/p>\n<p>Malte Benfeldt, Konrad Jankie\u00adwicz (both M&amp;A), Dr. Enno Burk (Part\u00adner), Chris\u00adtoph Schoppe, Sophie R\u00f6mer (all Health\u00adcare &amp; Life Scien\u00adces), Dr. Rut Stein\u00adhau\u00adser (Part\u00adner), Angela Tschech (both Employ\u00adment Law), Jan Felix Hinrichs (IP\/Tech, all Berlin), Michael P. Clever (Real Estate Law, Frank\u00adfurt), Aylin Hoffs (Coun\u00adsel, Foreign Trade Law, D\u00fcsseldorf).<\/p>\n<p>Gleiss Lutz teams regu\u00adlarly advise inves\u00adtors and compa\u00adnies on large finan\u00adcing rounds in inno\u00adva\u00adtive future-orien\u00adted indus\u00adtries such as biotech\u00adno\u00adlogy, arti\u00adfi\u00adcial intel\u00adli\u00adgence and deep tech. Most recently, Gleiss Lutz advi\u00adsed TRUMPF SE on the entry of inves\u00adtors into its subsi\u00addiary Q.ANT.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Berlin\/ Zurich \u2014 The Belgian invest\u00adment and holding company Acker\u00admans &amp; van Haaren NV has inves\u00adted EUR 36 million in the biotech company DISCO Phar\u00admaceu\u00adti\u00adcals GmbH as co-lead inves\u00adtor in a seed finan\u00adcing round. Gleiss Lutz advi\u00adsed Acker\u00admans &amp; van Haaren NV compre\u00adhen\u00adsi\u00advely on this tran\u00adsac\u00adtion.&nbsp; Through its subsi\u00addiary AvH Growth Capi\u00adtal, Acker\u00admans &amp;&nbsp;van&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":58799,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-58801","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"Berlin\/ Zurich - The Belgian investment and holding company Ackermans &amp; van Haaren NV has invested EUR 36 million in the biotech company DISCO Pharmaceuticals GmbH as co-lead investor in a seed financing round. Gleiss Lutz advised Ackermans &amp; van Haaren NV on this transaction.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Berlin\/ Zurich - The Belgian investment and holding company Ackermans &amp; van Haaren NV has invested EUR 36 million in the biotech company DISCO Pharmaceuticals GmbH as co-lead investor in a seed financing round. Gleiss Lutz advised Ackermans &amp; van Haaren NV on this transaction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T18:26:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-15T18:26:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals\",\"datePublished\":\"2025-12-15T18:26:27+00:00\",\"dateModified\":\"2025-12-15T18:26:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/\"},\"wordCount\":329,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/\",\"url\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/\",\"name\":\"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png\",\"datePublished\":\"2025-12-15T18:26:27+00:00\",\"dateModified\":\"2025-12-15T18:26:54+00:00\",\"description\":\"Berlin\/ Zurich - The Belgian investment and holding company Ackermans & van Haaren NV has invested EUR 36 million in the biotech company DISCO Pharmaceuticals GmbH as co-lead investor in a seed financing round. Gleiss Lutz advised Ackermans & van Haaren NV on this transaction.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png\",\"width\":700,\"height\":560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals - FYB Financial Yearbook","description":"Berlin\/ Zurich - The Belgian investment and holding company Ackermans & van Haaren NV has invested EUR 36 million in the biotech company DISCO Pharmaceuticals GmbH as co-lead investor in a seed financing round. Gleiss Lutz advised Ackermans & van Haaren NV on this transaction.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals - FYB Financial Yearbook","og_description":"Berlin\/ Zurich - The Belgian investment and holding company Ackermans & van Haaren NV has invested EUR 36 million in the biotech company DISCO Pharmaceuticals GmbH as co-lead investor in a seed financing round. Gleiss Lutz advised Ackermans & van Haaren NV on this transaction.","og_url":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2025-12-15T18:26:27+00:00","article_modified_time":"2025-12-15T18:26:54+00:00","og_image":[{"width":700,"height":560,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png","type":"image\/png"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals","datePublished":"2025-12-15T18:26:27+00:00","dateModified":"2025-12-15T18:26:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/"},"wordCount":329,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/","url":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/","name":"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png","datePublished":"2025-12-15T18:26:27+00:00","dateModified":"2025-12-15T18:26:54+00:00","description":"Berlin\/ Zurich - The Belgian investment and holding company Ackermans & van Haaren NV has invested EUR 36 million in the biotech company DISCO Pharmaceuticals GmbH as co-lead investor in a seed financing round. Gleiss Lutz advised Ackermans & van Haaren NV on this transaction.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/12\/dr-martin-viciano-gofferje-gleiss-lutz.png","width":700,"height":560},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/ackermans-van-haaren-lead-investor-in-disco-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Ackermans &amp; van Haaren lead investor in DISCO Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/58801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=58801"}],"version-history":[{"count":1,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/58801\/revisions"}],"predecessor-version":[{"id":58802,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/58801\/revisions\/58802"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/58799"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=58801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=58801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=58801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}